Get the latest tech news
The Crackdown on Compounded GLP-1 Meds Has Begun
Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” versions of its meds.
With so many potential patients eager to get on GLP-1 medications, the shortage of both tirzepatide and semaglutide (the active ingredient in Ozempic and Wegovy) left a huge opening in the market. In the wake of the shortage ending, some telehealth companies offering the medication encouraged patients to order expanded supplies of the drugs, meant to tide them over for multiple months. As these products are not technically direct copies of Eli Lilly’s offerings, some compounders may try to argue that they are still permitted to produce versions with additional active ingredients.
Or read this on Wired
